Since 1961, when the existence of Stem Cells was proven accidentally, regenerative medicine has bloomed, shrunk, contracted, been hated and misunderstood all at once.
In 2008, the Stem Cells and Regenerative Medicine Congress had its inaugural year in the United States. Combined with President Obama’s promise to move the regenerative medicine industry forward, the event has grown year after year to become the premier event for those active in this space.
At this year’s event the regenerative medicine industry is taking it to the next level and discussing how genomics is changing the field – and highlighting the commercialization and manufacturing stories that have helped spur the recent success.
Discover the future of the regenerative medicine industry with exclusive content.
Regenerative medicine isn’t just a story about science, it is a story about people. That story is just starting to get good. Personalized medicine? Regenerative medicine has been doing it for years. It’s about time the rest of the industry caught up.
Discuss the hottest industry topics and make new connections
Learn from the best and brightest in the industry.
With networking drinks receptions, 1-2-1 partnering, a networking app and speed networking... we've got it all! Take part in a variety of formal and informal opportunities.
Contact us today to secure your position as a partner, sponsor or exhibitor at the show.
This event is an opportunity to showcase your services to your target market. By sponsoring our event, you can develop relationships, make sales and raise your company's profile.
Sponsoring involves more than just a two day event. We have access to the Total BioPharma community of almost 250,000 people. You provide us with great content, and we'll distribute it through email, our blog and multiple social media channels.
Your success at the show is dependent on the quality relationships you build. Take a look at the delegate list before the event, decide who you want to meet and we'll make it happen.
At last years World Drug Safety Congress Europe 2014 event, Anca Miclea, Senior Specialist Medical Safety and Epidemiology Global Pharmacovigilance, Abbott laboratories, gave the presentation ...
The post Safety, pharmacoepidemiology and research in practice: assessment of causation appeared first on Total Biopharma.
Remsima Case Study: The importance of ADCC in assessing clinically relevant differences Authors: Dr. Daniel Galbraith, Chief Scientific Officer and Andy Upsall, Director of Technical ...
The post Biosimilars have caused a revolution in the development of biologic drugs appeared first on Total Biopharma.
Innovation and strategy for pharmaceutical, biotech and R&D